🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07486297
Starting soon Not applicable

Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure

NCT07486297 · tracked via the Priya Life Science China tracker
Sponsor
Huazhong University of Science and Technology
Phase
Not applicable
Started
2026-06-30
Last updated
2026-06-25

Condition(s) studied

Implantation Failure

Investigational drug(s) / intervention(s)

Placebo GroupAcupuncture group

Placebo Group: nonpenetrating placebo needles

Acupuncture group: indwelling intradermal needles

Study summary

To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of pressing therapy on the success rate in patients with recurrent implantation failure.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: 1. Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos). 2. Age: 20 to 40 years old. 3. Planning for a cycle involving the transfer of frozen-thawed embryos (FET). 4. Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC). 5. Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation. Exclusion Criteria: 1. Individuals planning to undergo preimplantation genetic diagnosis (PGD). 2. Recipients of egg donations. 3. Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms). 4. Patients with known embryo-related factors leading to implantation failure. 5. Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on). 6. Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more). 7. Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months. 8. Individuals with untreated hydrosalpinx; 9. Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/m2. 10. Men with severe abnormalities in semen quality. Individuals with a history of needle phobia.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei

More Huazhong University of Science and Technology trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07486297 on ClinicalTrials.gov ↗ ← All trials in China